Vimarsana
Biggest News Aggregation in the World

Page 3 - Alacyclovir News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Alacyclovir. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Alacyclovir Today - Breaking & Trending Today

Flu Cases Climbing as We Return to a More 'Typical' Season - Vimarsana News

Flu Cases Climbing as We Return to a More 'Typical' Season

Flu is still nothing to mess with, and officials are promoting the flu activity results as a reminder for people to get their flu shots as soon as possible.

COVID-19 Antivirals Can Trigger Viral Rebound - Vimarsana News

COVID-19 Antivirals Can Trigger Viral Rebound

Though antivirals are critical for reducing severe COVID-19 symptoms, researchers suggested that the medication may not always be needed for milder cases.

Paxlovid Doesn't Reduce Most Post-COVID Conditions - Vimarsana News

Paxlovid Doesn't Reduce Most Post-COVID Conditions

With the exception of venous thromboembolism and pulmonary embolism events, the antiviral drug did not reduce the incidence of post-COVID-19 conditions in a study of nearly 10,000 US veterans.

Pfizer to Price COVID Treatment Paxlovid at $1390 Per Course - Vimarsana News

Pfizer to Price COVID Treatment Paxlovid at $1390 Per Course

Pfizer on Wednesday said it will set the US price for its COVID-19 antiviral treatment Paxlovid at nearly $1400 per five-day course when it moves to commercial sales after government stocks run out, more than double what the government currently pays for it.

US Plans Shift of Merck COVID Treatment to Commercial Market - Vimarsana News

US Plans Shift of Merck COVID Treatment to Commercial Market

The government will stop distributing free doses of Merck's COVID-19 antiviral treatment molnupiravir by the middle of next month and expects it to be sold on the commercial market instead.